Synergistic Administration of Photothermal Therapy and Chemotherapy to Cancer Cells Using Polypeptide-Based Degradable Plasmonic Matrices

Huang, Huang‐Chiao; Yang, Yoonsun; Nanda, Alisha; Koria, Piyush; Rege, Kaushal

doi:10.2217/nnm.10.133

Cited by 60 publications

(56 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This difference in superficial charge can be attributed to the presence of MB on the surface of the nanoparticle. Similar work has been reported in literature where MB is encapsulated in PLGA using different encapsulation methods, and sizes range from 190 to 220 nm, with zeta potentials ranging between -38 mV and -17.5 mV [3]. When encapsulating 2.5% TDL, authors have obtained 220 to 266 nm diameters with PDI values of 0.19 and 0.4 [1].…”

supporting

confidence: 83%

Methylene Blue Loaded PLGA Nanoparticles: Combined Emulsion, Drug Release Analysis and Photodynamic Activity

et al. 2017

View full text Add to dashboard Cite

The use of polymeric nanoparticles for the control release of photosensitizer compounds such as methylene blue represents a promising option for cancer treatment. Methylene blue (MB) has been of great interest in many areas of clinical medicine, from neurological disorders to cancer chemotherapy [1][2]. It can be used in photodynamic therapy, which consists on the application of MB in the area of interest, and then activated by light at 665 nm producing reactive oxygen species that leads to the death of the target cell via oxidative damage. Polymeric nanoparticles loaded with methylene blue (MB-PNP) were prepared by using a combined emulsification technique [4][5]. Briefly, MB is dissolved in deionized water and into a DCM solution containing MB and PLGA. The mixture is emulsified at 22% of amplitude (26.5 µm) by sonication. Next, an aqueous solution of 5% w/v PVA is added into the mixture and a second emulsification is carried during at 75% amplitude (90 µm). The solvent is evaporated under magnetic stirring, at room temperature. MB-PNPs are washed by three centrifugation cycles and freeze-dried for further characterization. All experiments were performed by triplicate.Nanoparticle size distribution and zeta potentials were measured using a zetasizer Nano ZS equipment (Malvern) by dynamic light scattering and laser Doppler electrophoresis, respectively. Average values of particle size obtained were 180 nm with 0.030 polydispersity index (PDI) and 190 nm with 0.109 PDI for blank PNP and 12% TDL MB-PNP respectively. Zeta potential values obtained were -31.2 mV for blank-PNP and -18.2mV for MB-PNP. This difference in superficial charge can be attributed to the presence of MB on the surface of the nanoparticle. Similar work has been reported in literature where MB is encapsulated in PLGA using different encapsulation methods, and sizes range from 190 to 220 nm, with zeta potentials ranging between -38 mV and -17.5 mV [3]. When encapsulating 2.5% TDL, authors have obtained 220 to 266 nm diameters with PDI values of 0.19 and 0.4 [1]. Other materials have also been used to encapsulate MB such as silica nanoparticles, resulting in diameters of particle of 105 nm, with zeta potentials between -44 and -29 mV [5]. Surface morphology of MB-PNP was analysed by scanning electron microscopy (JEOL) (Figure 1). The drug loading (DL) for MB-PNP was 0.97 %, resulting in a 8.06 % encapsulation efficiency (EE). Cannavà et al. obtained drug loadings values of 0.52 % to 1.13 % and encapsulation efficiencies of 3.13 % to 6.75 % [1]. These values are comparable to the ones obtained in this work. Encapsulation efficiency depends on the amount of drug used at the beginning of the formulation, meaning that less MB was used in the formulation in order to obtain the drug load desired.To evaluate in vitro MB release from MB-PNPs, the dialysis method is used [1]. MB concentrations were quantified by spectrometry at 665 nm using a calibration curve. During the study, the amount of MB released in the initial burst stage was 21 µg, which corresp...

show abstract

supporting

confidence: 83%

Methylene Blue Loaded PLGA Nanoparticles: Combined Emulsion, Drug Release Analysis and Photodynamic Activity

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Thus, it appears that targeting Hsp90 may lead to new approaches to prevent and/or treat castration-resistant prostate cancer (115). Alternatively, co-administration of hyperthermia and 17-AAG released from plasmonic matrices was a powerful approach for the ablation of malignant cells and can be used in the form of similar combinations of nanoparticles and chemotherapeutic drugs for a variety of malignancies (116). For the complete list of breast, ovarian and prostate cancer cell response to combination of Hsp90 inhibitor and another therapy (treatment) in vitro and/or in vivo see Table IV.…”

Section: Combination Of Hsp90 Inhibitor With Second Therapymentioning

confidence: 99%

Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (Review)

Solárová¹,

Mojžiš²,

Solár³

2014

Int J Oncol

View full text Add to dashboard Cite

Abstract. Hsp90 is a molecular chaperone that maintains the structural and functional integrity of various client proteins involved in signaling and many other functions of cancer cells. The natural inhibitors, ansamycins influence the Hsp90 chaperone function by preventing its binding to client proteins and resulting in their proteasomal degradation. Nand C-terminal inhibitors of Hsp90 and their analogues are widely tested as potential anticancer agents in vitro, in vivo as well as in clinical trials. It seems that Hsp90 competitive inhibitors target different tumor types at nanomolar concentrations and might have therapeutic benefit. On the contrary, some Hsp90 inhibitors increased toxicity and resistance of cancer cells induced by heat shock response, and through the interaction of survival signals, that occured as side effects of treatments, could be very effectively limited via combination of therapies. The aim of our review was to collect the data from experimental and clinical trials where Hsp90 inhibitor was combined with other therapies in order to prevent resistance as well as to potentiate the cytotoxic and/or antiproliferative effects.

show abstract

“…53,56 This aids in overcoming any potential hyperthermic resistance that may exist in various cancer subtypes. [57][58][59] However, to effectively utilize this combination therapy, the nanoparticles need to successfully penetrate into the core of the tumor embolic structures that exist in IBC. This study found that for SUM149 and rSUM149 cell lines, nanoparticles were homogenously distributed throughout the tumor embolic structure, as confirmed by MPM and histopathological staining.…”

mentioning

confidence: 99%

Photothermal ablation of inflammatory breast cancer tumor emboli using plasmonic gold nanostars

Crawford¹,

Shammas²,

Fales³

et al. 2017

IJN

View full text Add to dashboard Cite

Inflammatory breast cancer (IBC) is rare, but it is the most aggressive subtype of breast cancer. IBC has a unique presentation of diffuse tumor cell clusters called tumor emboli in the dermis of the chest wall that block lymph vessels causing a painful, erythematous, and edematous breast. Lack of effective therapeutic treatments has caused mortality rates of this cancer to reach 20%–30% in case of women with stage III–IV disease. Plasmonic nanoparticles, via photothermal ablation, are emerging as lead candidates in next-generation cancer treatment for site-specific cell death. Plasmonic gold nanostars (GNS) have an extremely large two-photon luminescence cross-section that allows real-time imaging through multiphoton microscopy, as well as superior photothermal conversion efficiency with highly concentrated heating due to its tip-enhanced plasmonic effect. To effectively study the use of GNS as a clinically plausible treatment of IBC, accurate three-dimensional (3D) preclinical models are needed. Here, we demonstrate a unique in vitro preclinical model that mimics the tumor emboli structures assumed by IBC in vivo using IBC cell lines SUM149 and SUM190. Furthermore, we demonstrate that GNS are endocytosed into multiple cancer cell lines irrespective of receptor status or drug resistance and that these nanoparticles penetrate the tumor embolic core in 3D culture, allowing effective photothermal ablation of the IBC tumor emboli. These results not only provide an avenue for optimizing the diagnostic and therapeutic application of GNS in the treatment of IBC but also support the continuous development of 3D in vitro models for investigating the efficacy of photothermal therapy as well as to further evaluate photothermal therapy in an IBC in vivo model.

show abstract

Synergistic Administration of Photothermal Therapy and Chemotherapy to Cancer Cells Using Polypeptide-Based Degradable Plasmonic Matrices

Cited by 60 publications

References 33 publications

Methylene Blue Loaded PLGA Nanoparticles: Combined Emulsion, Drug Release Analysis and Photodynamic Activity

Methylene Blue Loaded PLGA Nanoparticles: Combined Emulsion, Drug Release Analysis and Photodynamic Activity

Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (Review)

Photothermal ablation of inflammatory breast cancer tumor emboli using plasmonic gold nanostars

Contact Info

Product

Resources

About